Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Saccadic Behaviour in an Eye-Tracking Task is Differentially Altered by Neurodegenerative Diseases
Aging, Dementia, and Behavioral Neurology
P9 - Poster Session 9 (12:00 PM-1:00 PM)
10-004
Characterize saccadic behaviour across several neurodegenerative diseases to determine patterns of behavioural alterations that may be used as disease-specific biomarkers.
The overlap of oculomotor circuitry and brain regions affected by neurodegenerative disease suggests assessment of eye movements can differentiate and monitor such diseases. Typifying saccadic behavioural “fingerprints” found in neurodegenerative diseases, in combination with clinical measures, may enhance screening, diagnosis, and tracking of disease progression.
The Ontario Neurodegenerative Disease Research Initiative has collected data from individuals with one of six neurodegenerative diseases: Alzheimer’s disease (AD), mild cognitive impairment (MCI), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and vascular cognitive impairment (VCI). Patients (n=520, age 40-87) and a cohort of healthy age-matched controls (n=133, age 50-93) completed a randomly interleaved pro- and anti-saccade task while their eye movements were tracked with high-speed video. The colour of a central fixation point conveyed the instruction for a prosaccade (look at peripheral target) or antisaccade (look away from peripheral target). We assessed saccade parameters including task errors, reaction times, and their association with clinical parameters (e.g. MoCA score).
Patterns of abnormality differed across disease groups. Each group displayed abnormalities on a unique subset of task-related parameters – e.g., antisaccade reaction time significantly increased in PD and VCI relative to controls; antisaccade direction errors (erroneously looking at the peripheral target) at very short latencies significantly increased in FTD and PD; and fixation breaks (looking away from the fixation point) significantly increased in AD and VCI. A subset of performance parameters (fixation breaks, antisaccade direction errors) were progressively worsened between controls, MCI, and AD.
Neurodegenerative diseases display unique oculomotor “fingerprints” that provide insight into disease-specific brain dysfunction. These fingerprints signify unique behavioural biomarkers for neurodegeneration that, in combination with clinical measures, can powerfully inform novel diagnostic tools and treatments.
Authors/Disclosures

PRESENTER 		No disclosure on file
No disclosure on file
No disclosure on file
Sandra E. Black, MD, FÂ鶹´«Ã½Ó³»­ (Sunnybrook Health Science Center) Dr. Black has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Hoffmann-La Roche. Dr. Black has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Black has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffmann-La Roche. Dr. Black has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Black has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai Limited . Dr. Black has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Black has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Black has received research support from Hoffmann-La Roche. The institution of Dr. Black has received research support from Biogen. The institution of Dr. Black has received research support from GE Healthcare. The institution of Dr. Black has received research support from Eli Lilly. The institution of Dr. Black has received research support from Genentech. The institution of Dr. Black has received research support from NovoNordisk. The institution of Dr. Black has received research support from UCB Biopharma. The institution of Dr. Black has received research support from Alkahest Inc. The institution of Dr. Black has received research support from University of Southern California - AHEAD 3-45 Study.
No disclosure on file
Dariush Dowlatshahi, MD (University of Ottawa) Dr. Dowlatshahi has nothing to disclose.
Elizabeth Finger, MD, FÂ鶹´«Ã½Ó³»­ Dr. Finger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vigil Neuro. Dr. Finger has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Denali Therapeutics. The institution of Dr. Finger has received research support from CIHR. The institution of Dr. Finger has received research support from Physician Servcices Incorporated. The institution of Dr. Finger has received research support from Weston Foundation. Dr. Finger has received personal compensation in the range of $500-$4,999 for serving as a Annual Meeting Course Director with Â鶹´«Ã½Ó³»­.
Morris Freedman, MD, FÂ鶹´«Ã½Ó³»­ (Baycrest Health Sciences) No disclosure on file
No disclosure on file
Anthony E. Lang, MD, FÂ鶹´«Ã½Ó³»­ (Toronto Western Hospital) Dr. Lang has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AbbVie, Amylyx, Aprinoia, Biogen, BioAdvance, Biohaven, BioVie, BlueRock, BMS, Denali, Janssen, Lilly, Pharma 2B, Sun Pharma, and UCB. Dr. Lang has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for medicolegal cases related to paraquat. The institution of Dr. Lang has received research support from AbbVie. Dr. Lang has received intellectual property interests from a discovery or technology relating to health care. Dr. Lang has received publishing royalties from a publication relating to health care.
Connie C. Marras, MD (Toronto Western Hospital) Dr. Marras has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine Biosciences. The institution of Dr. Marras has received research support from Theravance Inc. The institution of Dr. Marras has received research support from Centogene.
Mario Masellis, MD (Sunnybrook Health Sciences Centre) Dr. Masellis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arkuda Therapeutics. Dr. Masellis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Masellis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alector. Dr. Masellis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Wave Life Sciences. The institution of Dr. Masellis has received research support from Canadian Institutes of Health Research. The institution of Dr. Masellis has received research support from Ontario Brain Institute. The institution of Dr. Masellis has received research support from Weston Brain Institute. The institution of Dr. Masellis has received research support from Washington University. The institution of Dr. Masellis has received research support from Alector. Dr. Masellis has received publishing royalties from a publication relating to health care.
Christen L. Shoesmith, MD, BSc, FÂ鶹´«Ã½Ó³»­ (University Hospital) The institution of Dr. Shoesmith has received research support from AL-Pharma. The institution of Dr. Shoesmith has received research support from Mitsubishi Tanabe. The institution of Dr. Shoesmith has received research support from Cytokinetics. The institution of Dr. Shoesmith has received research support from Sanofi. The institution of Dr. Shoesmith has received research support from Neurosense. The institution of Dr. Shoesmith has received research support from Regeneron. Dr. Shoesmith has a non-compensated relationship as a Canadian ALS Research Consortium Chair with ALS Canada that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Richard H. Swartz, BSc MD PhD FRCPC (Sunnybrook Health Sciences Centre) The institution of Dr. Swartz has received research support from Heart and Stroke Foundation of Canada. The institution of Dr. Swartz has received research support from Ontario Brain Institute.
No disclosure on file
Carmela Tartaglia, MD (Toronto Western Hospital, University of Toronto) Dr. Tartaglia has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. The institution of Dr. Tartaglia has received research support from NIH. The institution of Dr. Tartaglia has received research support from University of Toronto.
Lorne H. Zinman, MD Dr. Zinman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, MTP, AB Science, Cytokinetics, Amylyx. Dr. Zinman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx.
No disclosure on file
No disclosure on file